Pathstone Holdings’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Pathstone Holdings’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,797,661	Closed	-$1.83M	–	2405
2024 Q4	$1.83M	Buy	+2,797,661	New	+$1.14M	0.01%	1020

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Pathstone Holdings's NKGN Position: Q1 2025 in Review

Pathstone Holdings sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 2,797,661 shares — an estimated $1.83M sold.

Pathstone Holdings first reported a position in NKGN in Q4 2024 and held it in 1 quarter. The position peaked at $1.83M in Q4 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Pathstone Holdings reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Pathstone Holdings sold 2,797,661 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $1.83M.
Pathstone Holdings first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Pathstone Holdings's NKGen Biotech, Inc. Common Stock position peaked at $1.83M in Q4 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Pathstone Holdings's 13F filing for Q1 2025, filed 15 May 2025.